Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

196.52 +1.02 (+0.52%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

48 49 Next >

Biogen's Earnings Outlook ↗

July 19, 2022

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Wednesday, 2022-07-20. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report...

Via Benzinga

Analyst Ratings for Biogen ↗

July 18, 2022

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Via Benzinga

Bank Of America And Goldman Sachs Split On Earnings Reports, Possibly Putting Bank Rally In Jeopardy ↗

July 18, 2022

(Monday Market Open) Investors around the globe appear to be starting the new trading week with a positive attitude as Asian and European markets traded higher overnight helping to boost U.S. equity...

Via Benzinga

Why Scholar Rock Shares Are Trading Higher Today ↗

June 17, 2022

Via Benzinga

Tesla, Twitter, Goldman Among Headline Earnings Of Unfolding Week: Here Are The Key Earnings Ahead ↗

July 17, 2022

The June quarter reporting season is entering its second week, with the focus gradually shifting from banks to technology companies.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 15, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Another Way To Understand Market Momentum ↗

July 15, 2022

(Friday Market Open) U.S. equity futures moved higher early Friday as investors digested better-than-expected June retail sales data and China’s worst GDP numbers since the start of the pandemic. Later...

Via Benzinga

Hot Inflation And Earnings Misses Weigh On Equity Futures ↗

July 14, 2022

(Thursday Market Open) The equity markets may take another hit today as JPMorgan Chase (NYSE: JPM) and Morgan Stanley (NYSE: MS) kicked off a new earnings season with a couple of misses as eq

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

July 14, 2022

Biogen's (NASDAQ:BIIB) short percent of float has fallen 4.95% since its last report. The company recently reported that it has 2.52 million shares sold short, which is 1.73% of...

Via Benzinga

The Fed's Pickle: Whether to Raise Rates to Fight Inflation While Increasing Recession Chances ↗

July 13, 2022

(Wednesday Market Open) The June Consumer Price Index (CPI) came in much hotter than expected, and equity index futures tumbled before the open.

Via Benzinga

Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗

July 12, 2022

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.87% on an annualized basis producing an average annual return of 10.15%. Currently, Biogen has a market capitalization of...

Via Benzinga

Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why ↗

July 11, 2022

The company's IPF treatment is proving itself where others didn't.

Via Investor's Business Daily

The 3 Leaders of the Gene Editing Revolution ↗

July 08, 2022

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.

Via InvestorPlace

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

3 Biotech Stocks to Sell Now ↗

July 05, 2022

These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead.

Via InvestorPlace

EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform ↗

June 30, 2022

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.

Via Benzinga

Peering Into Biogen's Recent Short Interest ↗

June 28, 2022

Biogen's (NASDAQ:BIIB) short percent of float has risen 9.27% since its last report. The company recently reported that it has 2.41 million shares sold short, which is 1.65% of...

Via Benzinga

Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today ↗

June 27, 2022

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of...

Via Benzinga

7 Biotech Stocks With Key Catalysts Coming in July ↗

June 27, 2022

Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

June 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover? ↗

June 16, 2022

Roche hoped to prevent Alzheimer's disease in patients with a genetic defect.

Via Investor's Business Daily

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement ↗

June 15, 2022

Via Benzinga

Analyzing Biogen's Short Interest ↗

June 10, 2022

Biogen's (NASDAQ:BIIB) short percent of float has risen 8.63% since its last report. The company recently reported that it has 2.20 million shares sold short, which is 1.51% of...

Via Benzinga

$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today ↗

June 09, 2022

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of...

Via Benzinga

7 No-Brainer Biotech Stocks to Add to Your Buy List ↗

June 09, 2022

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.

Via InvestorPlace

Quant Ratings Updated on 66 Stocks ↗

June 06, 2022

Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.

Via InvestorPlace

Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same ↗

June 01, 2022

Sage and Biogen say their MDD drug met every goal in a study of postpartum women.

Via Investor's Business Daily

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

Headline News about Biogen Idec

Starting at $3.75/week.

Subscribe Today